New support from Bpifrance for €1.5M, covering the GMP production of the Drug Substance OptPA, has been obtained

Op2Lysis was awarded a Deeptech Development Grant (ADD) to manufacture the clinical batch of OptPA, the active substance in O2L-001, for phase 1/2 in patients suffering from cerebral haemorrhage. The press release: